JPGN Reports
Cure8 research brief
Why This Matters
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when discussing monitoring strategies and expectations for infliximab therapy in children.
Who Should Pay Attention
Pediatric patients with Crohn's disease, parents/caregivers, pediatric gastroenterologists, clinicians managing biologic therapy, and researchers studying therapeutic drug monitoring or biomarkers in IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study looked at 79 pediatric patients treated with infliximab at one Australian centre between 2019–2021. Proactive TDM was performed at induction, end of induction, and then every 6 months; the main outcome was switching to another biologic within 2 years. Most patients remained on infliximab at 1 and 2 years.
Nine patients switched biologics (median 57 weeks). Higher post‑induction calprotectin (>305 µg/g), colonic phenotype, and need for escalated induction were reported as predictors of switching.
The report is an abstract-level clinical study (retrospective cohort) from a single centre, so results are useful for hypothesis generation and may inform discussions about proactive TDM but are not definitive proof of benefit across settings.
Keep In Mind
Retrospective single‑centre cohort (79 patients) with proactive TDM at defined timepoints; findings are from abstract/full‑text at the journal level but represent a specific centre's practice and require validation in larger, multicentre or prospective studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJPGN Reports
AuthorsCher Wei Chuah, Jessica Eldredge, Annabel Magoffin +7 more
InstitutionChildren's Hospital at Westmead
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...